The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia
Molecular and Cellular Endocrinology · 2024
DOI: 10.1016/j.mce.2023.112113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024. Verfasst von Cheng-Xu Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu 730000, China; The First Clinical Med…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Papillary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Lanzhou University, Natural Science Foundation of Gansu Province.
Abstract (Originalsprache)
Although disorders of primary cilia (PCs) were first reported in human papillary thyroid cancer (PTC) tissues in 1987, their precise role in PTC remains unclear. PCs sense the thyroid follicle colloid environment and act as a cell signaling hub. The present study investigated whether PCs are needed for BRAFV600E-driven PTC. We assessed whether BRAFV600E protein expression correlates with papillary histological architecture and clinicopathological features of PTC. We found that expression of ciliary intraflagellar transport 88 (IFT88) and PC formation were reduced in BRAFV600E-driven PTCs and that loss of cilia may be associated with lymph node metastasis. In PTC cells, the BRAFV600E mutation maintained the aggressiveness of PTC, which was partially related to loss of PCs. Our work confirms that BRAFV600E mutation-driven PC downregulation contributes to maintaining the aggressiveness of PTCs and that manipulating PC can potentially reduce the adverse incidence of PTC in a range of conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu 730000, China; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, China.
- College of Integrated Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, China.
- Department of Endocrinology & Nutrition, CIBERDEM, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, 08041 Barcelona, Spain. Electronic address: DMauricio@santpau.cat.
- Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu 730000, China; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, China. Elec…
Förderung
- Lanzhou University
- Natural Science Foundation of Gansu Province
Zitieren
APA
Ma, C. X., Ma, X. N., Liu, J. J., Guan, C. H., Li, Y. D., Zhao, N., Mauricio, D., & Fu, S. B. (2024). The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2023.112113
Vancouver
Ma CX, Ma XN, Liu JJ, Guan CH, Li YD, Zhao N, et al. The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia. Molecular and Cellular Endocrinology. 2024. doi:10.1016/j.mce.2023.112113
BibTeX
@article{Ma2024,
author = {Ma, Cheng-Xu and Ma, Xiao-Ni and Liu, Jin-Jin and Guan, Cong-Hui and Li, Ying-Dong and Zhao, Nan and Mauricio, Dídac and Fu, Song-Bo},
title = {The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
doi = {10.1016/j.mce.2023.112113}
}
EUVIMED